Author

Richard Kurupi

Virginia Commonwealth UniversityORCID 0000-0002-7727-4865Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cell type annotation· 1 Assay:DNA methylation· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1

Frequent Co-Authors

Anthony C. FaberiD· 2 shared Bin Hu· 2 shared Jamie M. Slaughter· 2 shared Jennifer E. KoblinskiiD· 2 shared Konstantinos V. FlorosiD· 2 shared Krista M. DaltoniD· 2 shared Kun ZhangiD· 2 shared Madelyn R. Lorenz· 2 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Anthony C. FaberORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Daraxonrasib (RMC-6236) is an effective targeted therapy for RAS-mutant neuroblastoma

Ronald D. Hill, Krista M. Dalton, Richard Kurupi, Jamie M. Slaughter, Jane Roberts, Yanli Xing, Victor Kehinde, Kun Zhang, Bin Hu, Vita Kraskauskiene, Madelyn R. Lorenz, Jennifer E. Koblinski, Mikhail G. Dozmorov, Konstantinos V. Floros, Anthony C. Faber

This study shows that Daraxonrasib (RMC-6236) effectively targets RAS-mutant neuroblastoma by inhibiting MAPK signaling and enhancing cell death.

bioRxiv · Feb 20, 2026 · PreprintCancer Biology

Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in Synovial Sarcoma

Konstantinos V. Floros, Carter K. Fairchild, Jinxiu Li, Kun Zhang, Jane L. Roberts, Richard Kurupi, Durga Paudel, Yanli Xing, Bin Hu, Vita Kraskauskiene, Nayyerehalsadat Hosseini, Shanwei Shen, Melissa M. Inge, Kyllie Smith-Fry, Li Li, , Anthony C. Faber

This study shows that inhibiting SUMOylation with TAK-981 stabilizes cBAF complexes and disrupts the SS18::SSX-driven transcriptome in synovial sarcoma, leading to tumor inhibition.

Nature Communications · Nov 5, 2025Peer-reviewedCancer Biology